Hormonal
The peptide triple agonist GEP44, targeting GLP-1, Y1, and Y2 receptors, promotes profound weight loss and glycemic control in diet-induced obese rats without triggering the nausea or malaise associated with standard GLP-1 receptor agonists.
This research highlights a promising new class of drugs (triple agonists like GEP44) that may offer superior weight loss and blood sugar control compared to current GLP-1 medications, without causing the nausea that often stops people from taking them. However, this is currently only proven in animals, not humans. For now, standard GLP-1s remain the primary option, but patients experiencing intolerable side effects might discuss clinical trials or future availability of these multi-agonists with their healthcare provider.
Administration of GEP44 resulted in potent anorectic effects... resulting in an 80% reduction in food intake and a more profound loss of body weight than what could be achieved in response to treatment with several of the US Food and Drug Administration (FDA)-approved GLP-1RAs... Furthermore, administration of GEP44 resulted in no visceral malaise, as determined in experiments with both rats and shrews
Why this rating
Evidence is derived from in vitro assays and preclinical animal models (rats/shrews), lacking human clinical trial data.
Source
A peptide triple agonist of GLP-1, neuropeptide Y1, and neuropeptide Y2 receptors promotes glycemic control and weight loss
Kylie S. Chichura et al. · Scientific Reports · 2023
DOI 10.1038/s41598-023-36178-1
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →